期刊名称：JOURNAL OF NEUROIMMUNE PHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Journal of Neuroimmune Pharmacology
ISSN: 1557-1890 (Print) 1557-1904 (Online)
Description
The Journal of Neuroimmune Pharmacology (JNIP) is the peer-reviewed journal of the Society on NeuroImmune Pharmacology. JNIP interfaces the disciplines of immunology, pharmacology and experimental neuroscience by acting as a platform for research discoveries into the pathogenesis and pharmacology of nervous system disorders affecting the immune system and vice versa. Original interdisciplinary scientific contributions, concise 'opinion,' and broad reviews are welcome. Research areas reporting in JNIP include receptor cell signaling, the pathobiology, cognitive neuroscience, psychopharmacology and immunity of drugs of abuse, neurodegenerative disorders, neurovirology, neuroimmunology, and neuropharmacology. Manuscripts must include original research linked to the immunology and pharmacology of human neurologic and neuropsychiatric disorders including substance abuse, depression, psychosis, Alzheimer's and Parkinson's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, HIV-associated neurocognitive disorders, neuroendocrine and microbial infections, and immunological, toxic and metabolic disorders of the brain, spinal cord, and peripheral nerves. Topical studies of brain-immune interactions include, but are not limited to: (1) leukocyte trafficking into the nervous system; (2) innate immunity in the nervous system; (3) pathophysiology of neurodegenerative diseases; (4) effects of endogenous ligands on brain-immune interactions (neuronal-peripheral immune; neuronal-glial); (5) effects of drugs of abuse and other pharmacophores on peripheral immune responses, (6) medicinal chemistry and drug development; (7) vaccine approaches for neurologic and neuropsychiatric diseases; (8) bioimaging and proteomics; (9) nanomedicine; and (10) immune surveillance for microbial infections. JNIP will identify novel pharmacologic discoveries (organized action of drug targets, mechanisms, and development) of brain-immune interactions with a potential towards modif, ying the cellular and systemic responses that affect disease or lead to amelioration of brain injury and immune dysfunction.
Related subjects » Cell Biology - Immunology - Neuroscience - Pharmacology & Toxicology - Virology
Abstracted/Indexed in
Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Google Scholar, CSA, Academic OneFile, AGRICOLA, Biological Abstracts, BIOSIS, ChemWeb, Gale, OCLC, SCImago, Summon by ProQuest
Aims and scope
The aims of the Journal of Neuroimmune Pharmacology are to promote the dissemination, interest, and exchange of new and important discoveries for the pharmacology and immunology of the nervous system. The aims parallel that of the Society on NeuroImmune Pharmacology by increasing the fundamental understanding of neurologic and neuropsychiatric disorders affected by the immune system or vice versa and towards pharmacologic measures that lead, either to a better understanding of disease mechanisms, or by improving disease outcomes. The scope of JNIP includes all primary works and reviews into the etiology, prevention, and treatment of neuroimmune and nervous system diseases affected by disordered immunity. Original studies serving to define neuroimmune modulation of environmental or endogenous cues such as toxins and drugs of abuse, hormones, and cytokines are welcome. JNIP will serve as a reliable source of interdisciplinary information bridging the fields of pharmacology, immunology, and neuroscience.
Instructions to Authors
Instructions for Authors
Types of papers
Original Article: No page limitations but usual length is 20-30 pages (double spaced) with up to 60 references and 8 figures plus tables
Invited reviews: 20-30 pages, double spaced with a minimum of 3 figures
Brief Report: 10 pages, double spaced with 2-3 figures and/ or tables
Perspectives: Eight to 12 pages that provides definitive research perspective and conclusion section. This would include up to two figures
Editor's choice commentary: 5-8 pages with no more than 12 references that comments on a selected paper and reviews its implications and field significance. Figures are not required
Guest editor commentary: A review of articles contained within a designated special issue with references listed for the accompanying publications. The length is 6-10 pages with acknowledgment, abstract and listed references. A head-shot figure of the editor in color should be included for publication
Letters to the Editor: No more than 1,000 words with a maximum of 10 references
Additional information
AUTHORSHIP CRITERIA AND CONTRIBUTION
The International Committee of Medical Journal Editors has recommended the following criteria for authorship
- Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.
- When a large, multi-center group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript (Flanagin et al., 2002). These individuals should fully meet the criteria for authorship defined above and editors will ask these individuals to complete journal-specific author and conflict of interest disclosure forms. When submitting a group author manuscript, the corresponding author should clearly indicate the preferred citation and should clearly identify all individual authors as well as the group name. Journals will generally list other members of the group in the acknowledgements. The National Library of Medicine indexes the group name and the names of individuals the group has identified as being directly responsible for the manuscript.
- Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship.
- All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
The Journal of Neuroimmune Pharmacology requires one or more authors, referred to as “guarantors,” be identified as the persons who take responsibility for the integrity of the work as a whole, from inception to published article, and publish that information.
Increasingly, authorship of multi-center trials is attributed to a group. All members of the group who are named as authors should fully meet the above criteria for authorship. The order of authorship on the byline should be a joint decision of the co-authors. Authors should be prepared to explain the order in which authors are listed.
CONFIDENTIALITY
The Journal of Neuroimmune Pharmacology handles all correspondence between editorial office, authors, and peer-reviewers in a confidential manner. Authors and reviewers are required to also handle all journal correspondence, critiques, and other confidential information in a confidential manner. Permission needs to be obtained from the editor prior to use of any confidential information.
INSTRUCTIONS FOR BRIEF COMMUNICATIONS
A Brief Communication is a significant piece of research that has been completed. It is not a note of preliminary results. The work may have time urgency, particularly if it is in a rapidly moving discipline, or it may be simply the publication of choice for work that can be published in a short format. It may also be one step in a continuing research program that merits a short note, but that is not yet fully developed for full paper status. In some instances, a major research paper may follow that incorporates and builds upon the Brief Communication.
Manuscripts for Brief Communication must be submitted online via Editorial Manager. Please identify the submission as a Brief Communication. Brief Communications are limited to four journal pages, including a maximum of two inserts (figures or tables) and fifteen references. The text of the article should not exceed 2000 words. Abstracts should not exceed 150 words. Accepted submissions for Rapid Communications are considered final. Follow all formatting instructions as for a regular communication, as stated above.
GUIDELINES FOR REVIEWS
Reviews are brief (limit of 6 double-column printed pages, i.e., approximately 4000 words), 10 pages for reviews (approximately 7000 words, exclusive of references) biographical profiles, historical perspectives, or summaries of developments in fast-moving areas. They must be mostly based on published articles, but can also include some unpublished material from the author(s) that may be useful to round off the perspective; they may address any subject within the scope of the journal.
Reviews may be either solicited or proffered by authors responding to a recognized need. Irrespective of origin, Reviews are subject to review and should be submitted via Editorial Manager. Please identify the submission as a Review.
Reviews should have an abstract highlighting the main conclusions from the reviewed material.
Book reviews, invited by the editor, should be one-page (inclusive of references) wide-perspective evaluation of recent books in the scope of the journal.
FOR METHODS AND PROTOCOLS PAPERS:
All methods and protocols papers must follow the below structure:
- I. Summary/Abstract
II. Keywords
III. Introduction
IV. Materials:
V. Methods
VI. Notes
VII. References
For protocol samples and more in-depth instructions, please visit:
RESUBMISSION OF MANUSCRIPTS
Authors are provided critiques after review. Manuscripts that require minor revisions have 30 days to submit revisions; manuscripts that require major revisions have 90 days to submit revisions. Authors unable to meet these time frames are encouraged to contact the Editorial Office (jnip@unmc.edu). A point-by-point response to critiques should accompany all resubmitted manuscripts. Decisions of acceptance on minor reviews are made by the EIC or Senior Editor; for major revisions, the paper is peer reviewed.
MANUSCRIPT SUBMISSION
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.
Title page
Title Page
The title page should include:
- The name(s) of the author(s)
- A concise and informative title
- The affiliation(s) and address(es) of the author(s)
- The e-mail address, telephone and fax numbers of the corresponding author
Abstract
Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.
Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.
Text
Text Formatting
Manuscripts should be submitted in Word.
- Use a normal, plain font (e.g., 10-point Times Roman) for text.
- Use italics for emphasis.
- Use the automatic page numbering function to number the pages.
- Do not use field functions.
- Use tab stops or other commands for indents, not the space bar.
- Use the table function, not spreadsheets, to make tables.
- Use the equation editor or MathType for equations.
- Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Manuscripts with mathematical content can also be submitted in LaTeX.
Headings
Please use no more than three levels of displayed headings.
Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full.
Scientific style
Genus and species names should be in italics.
References
Citation
Cite references in the text by name and year in parentheses. Some examples:
- Negotiation research spans many disciplines (Thompson 1990).
- This result was later contradicted by Becker and Seligman (1996).
- This effect has been widely studied (Abbott 1991; Barakat et al. 1995; Kelso and Smith 1998; Medvec et al. 1999).
Reference list
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.
Reference list entries should be alphabetized by the last names of the first author of each work.
- Journal article
Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 105:731-738. doi: 10.1007/s00421-008-0955-8
Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted:
Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med 965:325–329
- Article by DOI
Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. doi:10.1007/s001090000086
- Book
South J, Blass B (2001) The future of modern genomics. Blackwell, London
- Book chapter
Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp 230-257
- Online document
Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007
- Dissertation
Trent JW (1975) Experimental acute renal failure. Dissertation, University of California
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see
For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.
TABLES
- All tables are to be numbered using Arabic numerals.
- Tables should always be cited in text in consecutive numerical order.
- For each table, please supply a table caption (title) explaining the components of the table.
- Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
- Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.
ARTWORK AND ILLUSTRATIONS GUIDELINES
For the best quality final product, it is highly recommended that you submit all of your artwork –
photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the
highest standards with the greatest accuracy to detail. The published work will directly reflect the
quality of the artwork provided.
Electronic Figure Submission
- Supply all figures electronically.
- Indicate what graphics program was used to create the artwork.
- For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.
- Vector graphics containing fonts must have the fonts embedded in the files.
- Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
Line Art
- Definition: Black and white graphic with no shading.
- Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
- All lines should be at least 0.1 mm (0.3 pt) wide.
- Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
- Vector graphics containing fonts must have the fonts embedded in the files.
Halftone Art
- Definition: Photographs, drawings, or paintings with fine shading, etc.
- If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
- Halftones should have a minimum resolution of 300 dpi.
Combination Art
- Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
- Combination artwork should have a minimum resolution of 600 dpi.
Color Art
- Color art is free of charge for online publication.
- If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
- If the figures will be printed in black and white, do not refer to color in the captions.
- Color illustrations should be submitted as RGB (8 bits per channel).
Figure Lettering
- To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
- Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
- Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
- Avoid effects such as shading, outline letters, etc.
- Do not include titles or captions within your illustrations.
Figure Numbering
- All figures are to be numbered using Arabic numerals.
- Figures should always be cited in text in consecutive numerical order.
- Figure parts should be denoted by lowercase letters (a, b, c, etc.).
- If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures,
"A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.
Figure Captions
- Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
- Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
- No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
- Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
- Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.
Figure Placement and Size
- When preparing your figures, size figures to fit in the column width.
- For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.
- For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 198 mm.
Permissions
If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.
Accessibility
- In order to give people of all abilities and disabilities access to the content of your figures, please make sure that
- All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
- Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)
- Any figure lettering has a contrast ratio of at least 4.5:1
ELECTRONIC SUPPLEMENTARY MATERIAL
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form.
Submission
- Supply all supplementary material in standard file formats.
- Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
- To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.
Audio, Video, and Animations
- Always use MPEG-1 (.mpg) format.
Text and Presentations
- Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
- A collection of figures may also be combined in a PDF file.
Spreadsheets
- Spreadsheets should be converted to PDF if no interaction with the data is intended.
- If the readers should be encouraged to make their own calculations, spreadsheets should be submitted as .xls files (MS Excel).
Specialized Formats
- Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.
Collecting Multiple Files
- It is possible to collect multiple files in a .zip or .gz file.
Numbering
- If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
- Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
- Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.
Captions
- For each supplementary material, please supply a concise caption describing the content of the file.
Processing of supplementary files
- Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.
Accessibility
In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that
- The manuscript contains a descriptive caption for each supplementary material
- Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)
Integrity of research and reporting
Ethical standards
Manuscripts submitted for publication must contain a statement to the effect that all human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
These statements should be added in a separate section before the reference list. If these statements are not applicable, authors should state: The manuscript does not contain clinical studies or patient data.
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements
Conflict of interest
All benefits in any form from a commercial party related directly or indirectly to the subject of this manuscript or any of the authors must be acknowledged. For each source of funds, both the research funder and the grant number should be given. This note should be added in a separate section before the reference list.
If no conflict exists, authors should state: The authors declare that they have no conflict of interest.
Does Springer provide English language support?
Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal style. This may not be sufficient if English is not your native language and substantial editing would be required. In that case, you may want to have your manuscript edited by a native speaker prior to submission. A clear and concise language will help editors and reviewers concentrate on the scientific content of your paper and thus smooth the peer review process.
The following editing service provides language editing for scientific articles in all areas Springer
publishes in:
Use of an editing service is neither a requirement nor a guarantee of acceptance for publication.
Please contact the editing service directly to make arrangements for editing and payment.
For Authors from China
文章在投稿前进行专业的语言润色将对作者的投稿进程有所帮助。作者可自愿选择使用Springer推荐的编辑服务，使用与否并不作为判断文章是否被录用的依据。提高文章的语言质量将有助于审稿人理解文章的内容，通过对学术内容的判断来决定文章的取舍，而不会因为语言问题导致直接退稿。作者需自行联系Springer推荐的编辑服务公司，协商编辑事宜。
For Authors from Japan
ジャーナルに論文を投稿する前に、ネイティブ・スピーカーによる英文校閲を希望されている方には、Edanz社をご紹介しています。サービス内容、料金および申込方法など、日本語による詳しい説明はエダンズグループジャパン株式会社の下記サイトをご覧ください。
For Authors from Korea
영어 논문 투고에 앞서 원어민에게 영문 교정을 받고자 하시는 분들께 Edanz 회사를 소개해 드립니다. 서비스 내용, 가격 및
신청 방법 등에 대한 자세한 사항은 저희 Edanz Editing Global 웹사이트를 참조해 주시면 감사하겠습니다.
After acceptance
Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice, offprints, or printing of figures in color.
Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.
Open Choice
In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink.
Copyright transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.
Offprints
Offprints can be ordered by the corresponding author.
Color illustrations
Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs.
Proof reading
The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.
Online First
The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.
Editorial Board
Editor-in-Chief:
Howard E. Gendelman
Carol Swarts, MD Emerging Neuroscience Research Laboratory
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, NE USA
hegendel@unmc.edu
Senior Editors:
Kalipada Pahan
Department of Neurological Sciences
Rush University Medical Center
Chicago, IL USA
Kalipada_Pahan@rush.edu
Bert 't Hart
Department of Immunobiology
Biomedical Primate Research Centre
Rijswijk, The Netherlands
Hart@bprc.nl
Section Editors:
Neuroactive and Abused Substances
Guy Cabral
Virginia Commonwealth University
Department of Microbiology and Immunology
1101 East Marshall Street
Richmond, Virginia, USA
gacabral@vcu.edu
Imaging and Biomarkers
Linda Chang
Department of Medicine
University of Hawaii
Honolulu, Hawaii, USA
ichang@hawaii.edu
Natural Medicine
Raymond Chuen-Chung Chang
Department of Anatomy
Faculty of Medicine
The University of Hong Kong,
Hong Kong SAR, China
rccchang@hku.hk
Visual Neuromedicine
Harris Gelbard
Center for Neural Development and Disease
University of Rochester Medical Center
Rochester, NY, USA
harris_gelbard@urmc.rochester.edu
Infectious Diseases and Immunomodulation
Steve Jacobson
Viral Immunology Section
Neuroimmunology Branch, NINDS
Bethesda, Maryland, USA
jacobsons@ninds.nih.gov
Drug Delivery and Developmental Therapeutics
Alexander Kabanov
Center for Nanotechnology in Drug Delivery
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, USA
kabanov@unc.edu
Neurodegenerative Disorders
Gary Landreth
Department of Neurosciences
Alzheimer Research Laboratory
Case Western University
Cleveland, Ohio, USA
gel2@po.cwru.edu
Cell Signaling and Immunity
Thomas J. Rogers
Fels Institute For Cancer Research And Molecular Biology
Department of Pharmacology
Temple University School of Medicine
Philadelphia, Pennsylvania, USA
rogerst@temple.edu
Managing Editor:
Robin Taylor
Project Coordinator
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, Nebraska, USA
email: jnip@unmc.edu
telephone: 402-559-3565
Editorial Board:
Martin Adler
Center for Substance Abuse Resources
Temple University School of Medicine
Philadelphia, Pennsylvania, USA
Aftab Ansari
Department of Pathology
Emory University School of Medicine
Atlanta, Georgia, USA
Stanley Appel
Department of Neurology
Methodist Neurological Institute
Houston, Texas, USA
Larry Benowitz
Department of Neurosurgery
Children's Hospital
Boston, Massachusetts, USA
Etty Benveniste
Department of Cell Biology
University of Alabama at Birmingham
Birmingham, Alabama, USA
Jean Bidlack
Department of Pharmacology and Physiology
University of Rochester Medical School
Rochester, New York, USA
Kathleen Boesze-Battaglia
Department of Biochemistry
University of Pennsylvania
Philadelphia, Pennsylvania, USA
Shilpa Buch
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, Nebraska, USA
Iain L. Campbell
University of Sydney
School of Molecular and Microbial Biosciences
Sydney, Australia
Sulie L. Chang
Department of Biological Sciences
Seton Hall University
South Orange, New Jersey, USA
Vladimir P. Chekhonin
Department of Biological Psychiatry
Moscow, Russia
Sheng-Di Chen
Department of Neurology
Rui Jin Hospital
Shanghai Jiaotong University School of Medicine
Shanghai, China
Carol Colton
Department of Neurology
Duke University
Durham, NC, USA
Marco Cosentino
Department of Clinical Medicine
University of Insubria
Varese, Italy
Ileana Cristea
Department of Molecular Biology
Princeton University
Princeton, New Jersey, USA
Tiziano Croci
Research Center Sanofi Midy
Milan, Italy
Toby Eisenstein
Temple University Medical Center
Philadelphia, Pennsylvania, USA
Ronald Ellis
Department of Neurosciences
University of California, San Diego
San Diego, California
Howard Fox
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, Nebraska, USA
Robert Fujinami
University of Utah
Salt Lake City, Utah, USA
Doina Ganea
Temple University
Philadelphia, Pennsylvania, USA
Gwenn Garden
University of Washington
Seattle, Washington, USA
Philippe Gasque
University of La Reunion
CYROI
St. Denis, Reunion Island
Kurt Hauser
Department Pharmacology and Toxicology
Virginia Commonwealth University
Richmond, Virginia, USA
Johnny He
Department of Microbiology and Immunology
Indiana University
Indianapolis, Indiana, USA
William F. Hickey
Department of Pathology
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, USA
Etienne Hirsch
Research Center of Brain and Spinal Cord
INSERM, CNRS and Pierre and Marie Curie University
Paris, France
WenZhe Ho
Department of Pathology and Laboratory Medicine
Temple University
Philadelphia, Pennsylvania, USA
Tsuneya Ikezu
Department of Pharmacology and Experimental Therapeutics
Boston University School of Medicine
Boston, Massachusetts, USA
Pooja Jain
Department of Microbiology and Immunology
Drexel University College of Medicine
Doylestown, Pennsylvania, USA
Anumantha Kanthasamy
College of Veterinary Medicine
Iowa State University
Ames, Iowa, USA
Peter G.E. Kennedy
Division of Clinical Neuroscience
Institute of Neurological Sciences University of Glasgow
Glasgow, UK
Dennis Kolson
Department of Neurology
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, USA
Anil Kumar
Division of Pharmacology
University of Missouri-Kansas City
Kansas City, Missouri, USA
Hans Lassmann
Medical University of Vienna
Center for Brain Research
Wien, Austria
Sunhee C. Lee
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
Department of Pathology
Bronx, NY, USA
Stuart Lipton
Department of Neurology
Burnham Institute Center for Neuroscience
LaJolla, CA, USA
Eugene Major
Laboratory of Molecular Medicine and Neuroscience
National Institute of Neurological Disease and Stroke
Bethesda, Maryland, USA
Eliezer Masliah
Departments of Neurosciences and Pathology
University of California, San Diego
LaJolla, CA, USA
Raphael Mechoulam
Department of Medicinal Chemistry and Natural Products
Hebrew University of Jerusalem
Jerusalem, Israel
Olimpia Meucci
Department of Pharmacology & Physiology
Drexel University College of Medicine
Philadelphia, Pennsylvania, USA
Richard Miller
Department of Molecular Pharmacology
Northwestern University
Chicago, IL, USA
David Morgan
Department of Pharmacology
University of South Florida
Tampa, Florida, USA
James O'Callaghan
Center for Disease Control and Prevention, NIOSH
Morgantown, West Virginia, USA
V. Hugh Perry
Biological Sciences
University of Southampton
Southampton, England, UK
Yuri Persidsky
Department of Pathology and Laboratory Medicine
Temple University
Philadelphia, PA
Phillip Peterson
Department of Medicine
Hennepin County Medical Center
Minneapolis, Minnesota, USA
Phillip Popovich
Department of Neuroscience
Ohio State University
Columbus, OH 43210
Stanley Prusiner
Institute for Neurodegenerative Diseases
University of California, San Francisco
San Francisco, California, USA
Serge Przedborski
Center for Neurobiology and Behavior
Columbia University
New York, New York, USA
Jay Rappaport
Center for Neurovirology and Cancer Biology
Temple University
Philadelphia, Pennsylvania, USA
Sabita Roy
Department of Pharmacology and Surgery
University of Minnesota
Minneapolis, Minnesota, USA
Virginia Sanders
College of Medicine and Public Health
Molecular Virology, Immunology and Medical Genetics
Ohio State University
Columbus, Ohio, USA
Michal Schwartz
Department of Neurobiology
The Weizmann Institute of Science
Rehovot, Israel
Burt Sharp
Department of Pharmacology
University of Tennessee Health Science Center
Memphis, Tennessee, USA
Bruce Shiramizu
University of Hawaii Medical Center
Manoa, Hawaii, USA
Prati Pal Singh
National Institute of Pharmaceutical Education and Research
Punjab, India
Gary Siuzdak
Center for Mass Spectrometry
The Scripps Research Institute
LaJolla, CA, USA
Christoph Stein
Department of Anesthesiology
Freie Universitaet Berlin
Berlin, Germany
Antonio Uccelli
Department of Experimental Medicine
University of Genoa and San Martino Hospital
Genoa, Italy
Linda Jo Van Eldik
Department of Anatomy and Neurobiology
University of Kentucky
Lexington, Kentucky, USA
Charles Wood
Nebraska Center for Virology
University of Nebraska Lincoln
Lincoln, Nebraska, USA
Bryan K. Yamamoto
Department of Neurosciences
University of Toledo College of Medicine
Toledo, Ohio, USA
Yaoying Zeng
Institute for Tissue Transplantation and Immunology
Jinan University, Guangzhou, China
Meet the Editors of JNIP
Meet the Editors of JNIP
The Journal of Neuroimmune Pharmacology is published under the leadership of a team of dedicated scientists. We invite you to meet the Editors by reading their biographical portraits below.
Howard E. Gendelman, Editor-in-Chief
Dr. Howard Gendelman is the Margaret R. Larson Professor of Medicine and Chair of the Department of Pharmacology and Experimental Neuroscience and Director of the Center for Neurodegenerative Disorders at the University of Nebraska Medical Center.
He received his medical degree from Pennsylvania State University followed by fellowship training and faculty appointments at the Albert Einstein College of Medicine, the Johns Hopkins University Medical Center, the National Institutes of Health, and the Walter Reed Army Institute of Research. He has gained international attention for his work on common mechanisms of nerve damage in Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis, and HIV-1-associated dementia.
His research has lead to groundbreaking discoveries on how inflammation causes nerve cell damage and how drugs and vaccines can be used to reverse it.
Kalipada Pahan, Senior Editor
Kalipada Pahan is a Professor of Neurological Sciences and the Floyd A. Davis Endowed Chair of Neurology in the Department of Neurological Sciences at the Rush University Medical Center in Chicago. Born in West Bengal, India, in 1964, he received his Ph.D. degree in Biochemistry in 1992 from the University of Calcutta, India, and pursued a postdoctoral training in Biochemistry and Neuroimmunology at the Medical University of South Carolina.
Dr. Pahan is engaged in translational research involving glial and neuronal cell signaling, proinflammatory transcription factors, nitric oxide, and ceramide with an emphasis on drug discovery for neuroinflammatory and neurodegenerative disorders such as multiple sclerosis, Parkinson's disease, Alzheimer's disease, HIV-associated dementia. He has over 100 publications including research articles, reviews and book chapters.
Bert A. ’t Hart, Senior Editor
Bert ’t Hart is a medical biologist by training (University of Utrecht, The Netherlands) and obtained his PhD in Immunology (Regulation of the activation and differentiation of human antigen-specific B cells) in 1986 under the supervision of prof. dr. Rudi Ballieux (University of Utrecht). After a postdoc research position in immunopharmacology (University of Utrecht), he joined in 1989 the primate research center in Rijswijk, The Netherlands. In 1998 he was appointed chairman of the Immunobiology department. The department develops and investigates non-human primate models of autoimmune inflammatory disorders (rheumatoid arthritis, multiple sclerosis) and neurodegenerative disease (Parkinson). The models are used for exploratory research into pathogenic mechanisms and the efficacy evaluation of new therapies.
As of January 2011 he holds a professorship in Neuroimmunology at the University Medical Center in Groningen. He is also a management team member of ErasMS, the Rotterdam center for translational research into MS.
Guy Cabral, Section Editor: Neuroactive and Abused Substances
Guy A. Cabral is a Professor in the Department of Microbiology and Immunology in the School of Medicine at Virginia Commonwealth University. He received the B. S. degree in Zoology from the University of Massachusetts (Amherst, MA) and the M.S. and Ph.D. degrees from the University of Connecticut (Storrs, Ct) and pursued postdoctoral training in virology at Baylor College of Medicine (Houston, TX).
Dr. Cabral’s research centers on assessment of immunomodulatory effects of drugs of abuse and other pharmacological agents on the immune system. Of particular interest has been definition of the role of cannabinoids in altering the activities of macrophages and macrophage-like cells, including microglia in the central nervous system. This focus has extended to investigating the functional relevance of cannabinoid receptors in host resistance to viral and opportunistic protozoon infections.
Linda Chang, Section Editor: Imaging and Biomarkers
Linda Chang is a Professor of Medicine at the University of Hawaii's John A. Burns School of Medicine, and Co-Director of the Neuroscience and Imaging Research Program at Queens Medical Center in Honolulu.
After completing her medical training at Georgetown University, Neurology Residency and Fellowships at UCLA, she was appointed as a Faculty member in 1992 in the Department of Neurology at UCLA School of Medicine. In 2000, she was recruited to serve as Chair of the Medical Department at Brookhaven National Laboratory, and in 2004, she relocated to Hawaii in order to continue her research in the effects of methamphetamine on the brain. She also received several honors and awards, including the Richard E. Weitzman Award in Biochemical Research in 1998 and the Brookhaven Woman of Science Award in 2001.
In addition, she received three career development awards from NIH, including the Clinical Associate Physician Award through the NCRR/GCRC program, and two Clinician Scientist Career Development Awards from NIDA. She is dedicated to both research and to mentor junior clinician scientists.
Her scientific interest and that of her laboratory included the application of advanced neuroimaging techniques [including MRI, positron emission tomography (PET) and SPECT] to investigate the neuropathophysiology of HIV, substance abuse, normal aging and development, as well as other neuropsychiatric disorders. Her research is supported by the NIH (NIDA, NIMH, NINDS, NCRR), the ONDCP and the University of Hawaii.
Raymond Chang, Section Editor: Natural Medicine
Dr. Raymond Chang received his BSc and MPhil in Biochemistry, Neurochemistry and Neuroanatomy in Hong Kong, China. His doctoral works were performed as a German Academic Exchange Student investigating neurophysiology and clinical neuroscience at the University of Munich, Munich, Germany. Postdoctoral training was performed in neuroimmunology, neuropharmacology, and molecular neuroscience at the National Institutes of Health, USA.
He has published over 90 peer-reviewed papers and book chapters in the field of neurosciences. His research interests currently center around works seeking to elucidate the molecular mechanisms of Alzheimer’s and Parkinson’s diseases (AD and PD) and their related neuroimmune responses. He heads the Laboratory of Neurodegenerative Diseases in Hong Kong that investigates the role played by beta-amyloid aggregation and autophagy in the pathobiology of AD. Mitochondria function and cellular clearing mechanisms including the ubiquitin proteasome system are actively studied with the goal in achieving the elimination of tau and other aggregated proteins that can induce disease.
These and other disease events are being investigated with an eye towards developing herbal medicines that would be used to slow or attenuate the severity or course of AD and PD. Studies of how such medicines can affect a broad range of aging co-morbidites in AD and PD are pursued that include depression, abused substances, obesity, hypertension and systemic inflammation. All can modulate neuroimmune responses that are linked to progressive age-related diseases.
Harris A. Gelbard, Section Editor: Visual Neuromedicine
Harris Gelbard is Professor of Neurology, Microbiology and Immunology, and Pediatrics and Director of the Center for Neural Development and Disease, University of Rochester Medical Center. Dr. Gelbard received his MD/PhD-Pharmacology in 1983 from Northwestern University Medical School, Chicago, Ill and joined the University of Rochester Medical Center in 1989.
Dr. Gelbard's research focuses on how HIV-1 and its constituent proteins disrupt the normal function(s) of two enzyme targets, glycogen synthase kinase 3 beta (GSK-3β) and mixed lineage kinase 3 (MLK3) in neurons, macrophages and microglia, with the ultimate goal of designing small molecule therapies to prevent their pathologic activation seen in neuroinflammatory and neurodegenerative disorders.
His research has made particularly important strides in developing striking visual presentations of research discovery. For example, he has adapted visual chronic thin-skull window methods for use in closely monitoring the biology, physiology, and molecular profiles of murine microglia in vivo over time using two-photon microscopy. His laboratory is at the cutting edge of visual experiments towards linking accessible translucent thinned-skull cortical windows for continuous observations of cellular events in the brain seen during disease and neurorepair.
He has over 20 years of continuous research support from the National Institutes of Health (NIMH, NINDS) and is well published in the fields of neuropharmacology, neurovirology, and neuroimmunity.
Steven Jacobson, Section Editor: Infectious Diseases and Immunomodulation
Dr. Jacobson received his B.A. from Temple University and his Ph.D. from the Rennselear Polytechnic Institute where he earned his degree in Virology. The focus of his research was on persistent virus infections.
In 1981, Dr. Jacobson joined the Neuroimmunology Branch as a postdoctoral research fellow in immunology as a National Multiple Sclerosis Society Fellow. In 1993, he received tenure and formed the Viral Immunology Section to study the role of human viruses in the pathogenesis of chronic progressive neurologic disease.
Dr. Jacobson's laboratory is studying virological, immunological, and molecular mechanisms associated with the human T lymphotropic virus type-I associated myelopathy/tropical spastic paraparesis and the association of virus in multiple sclerosis.
Alexander Kabanov, Section Editor: Drug Delivery and Developmental Therapeutics
Alexander Kabanov, born in Moscow, USSR in 1962, graduated with M.S. degree from M.V. Lomonosov Moscow State University (MSU) in 1984, obtained Ph.D. (1987) and D.Sc. (1990). Held academic positions in the School of Chemistry, MSU from 1987 to 1997, was appointed an adjunct professor in 2002. Since 1994, he has worked in the College of Pharmacy, University of Nebraska Medical Center, where currently is a Parke-Davis Professor and Director, Center for Drug Delivery and Nanomedicine. Co-founded Supratek Pharma Inc. in 1994. He has made substantial contributions in the fields of micellar enzymology, block polyelectrolyte complexes, nanomedicine, drug and gene delivery, and was one of the first to use synthetic polycations and polymeric micelles for DNA and drug delivery (1989), amphiphilic block copolymers to overcome multidrug resistance in cancer (1994), co-invented nanogels for the delivery of nucleic acids (1999), discovered effects of polymer excipients on pharmacogenomic responses – “polymer genomics” (2002). Has published over 150 papers, has over 100 patents worldwide. Awards include the Lenin’s Komsomol Prize (1988) and the NSF Career Award (1995).
Gary Landreth, Section Editor: Neurodegenerative Disorders
Dr. Landreth received his undergraduate degree in Chemistry and Biochemistry from the University of Kansas in 1972. He then completed a Ph.D. in the Neurosciences Program at the University of Michigan, including a year of study at the National Institute of Medical Research in London.
He did postdoctoral work in the Department of Neurobiology at Stanford. Dr. Landreth was appointed to the faculty of the Medical University of South Carolina, where he worked for 9 years. He moved to Case Western Reserve University and the Alzheimer Research Laboratory in 1989 and is currently a professor in the Department of Neurosciences. His work is focused on investigation of inflammatory mechanisms in Alzheimer's disease and the biology of microglia. The laboratory maintains a focus on drug development for CNS indications with an inflammatory component.
Thomas J. Rogers, Section Editor: Cell Signaling and Immunity
Thomas J. Rogers was born in Dayton, Ohio, home of Wilbur and Orville Wright, and earned his Ph.D. degree from the University of Wisconsin, Madison in 1976. After working as a post-doctoral fellow at the Roche Institute of Molecular Biology, he joined the faculty of the Microbiology Department at Oregon State University in 1978.
In 1981 he moved to Temple University School of Medicine as a faculty member in the Microbiology and Immunology Department. He is currently a member of the Department of Pharmacology, the Fels Institute for Cancer Research and Molecular Biology, and a Senior Investigator in the Center for Substance Abuse Research.
His research interests are in the regulation of G protein-coupled receptor expression and function, and the cross-talk between these receptors in the regulation of inflammatory processes. His most recent research efforts have focused on the interactions of opioid and chemokine receptors, and the regulation of expression of these receptors and their ligands. He is also interested in the role of cytokines and chemokines in the generation of inflammatory diseases, and inflammatory processes associated with microbial infections.
He has been the recipient of continuous funding from the National Institutes of Health since 1981. He has trained 20 doctoral students, 17 post-doctoral fellows during his academic career, and has a commitment to the training of young scientists.
Robin Taylor, Managing Editor
Robin Taylor is the Project Coordinator of the Department of Pharmacology and Experimental Neuroscience at the University of Nebraska Medical Center and Managing Editor of the Journal of Neuroimmune Pharmacology. Her computer, literary, and graphic skills play a seminal role in building the department. As Managing Editors for JNIP, Ms. Taylor's work supports the directives of the Editor-in-Chief, Section and Guest Editors to best facilitate the journal's development together with its outreach activities. She remains a mainstay of journal activities and its growth.
Message from the Editor-in-Chief
We are pleased to welcome you to the Journal of Neuroimmune Pharmacology (JNIP). Our goals are to report research discoveries that cross the boundaries of neuroscience, immunology and pharmacology. JNIP's focus is to report interdisciplinary research on neuroimmune pathways during disease and treatment of neurologic and neuropsychiatric disorders. Advances in cell signaling, biomarker discovery, neuroimmunology, molecular neuroscience, stem cell biology, nanomedicine and pharmacology are reflected in each of the journal's offerings. The broad vision seeks to translate the ideals of the Society on NeuroImmune Pharmacology (SNIP - www.s-nip.org) into a platform for opinion, debate, review and discovery. The realization of the means to combat and perhaps reverse the ravages of nervous system disorders remains a singular goal in reporting research discoveries
Howard E. Gendelman, M.D.
Editor-in-Chief
|
